Close Menu

NEW YORK – Swiss diagnostics firm ABCDx is developing a point-of-care blood test for stroke to enable faster diagnosis and treatment of the condition.

The Geneva-based company presented data from an ongoing clinical study of the test at the World Stroke Organization Conference (WSOC) held this week in Vienna. In data from 500 patients, the test was able to distinguish between sufferers of ischemic and hemorrhagic stroke with a sensitivity of 50 percent and a specificity of 100 percent.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.